Key result
Cryoballoon ablation for persistent AF is associated with ~80% symptom improvement despite high long-term recurrence.
Why the study?
Clinical outcomes of PVI have predominantly focused on AF recurrence and sinus rhythm maintenance, leaving limited intermediate follow-up data on health-related quality-of-life and symptom improvement in persistent AF.
Does pulmonary vein isolation using a second-generation cryoballoon improve freedom from atrial tachyarrhythmia and quality of life in patients with drug-refractory persistent atrial fibrillation?
Cross-Sectional (n=148)
No
Does pulmonary vein isolation using a second-generation cryoballoon improve freedom from atrial tachyarrhythmia and quality of life in patients with drug-refractory persistent atrial fibrillation?
Despite a 54.7% recurrence rate of atrial tachyarrhythmia at 3.7 years, pulmonary vein isolation using a second-generation cryoballoon significantly improved AF-related symptoms and quality of life in patients with persistent AF.
Answers are grounded in this paper and cite their sources.
May improve symptoms despite high recurrence in persistent AF; leaves open need for RCTs on long-term efficacy.
BACKGROUND: Clinical outcome of pulmonary vein isolation (PVI) has been predominantly focused on the reoccurrence of atrial fibrillation (AF) and the maintenance of sinus rhythm. However, there has been a limited intermediate follow-up on health-related quality-of-life (HRQoL) of patients. Given the relatively high recurrence rate of persistent AF after PVI treatment, it is important to follow up with clinical outcomes on symptom improvement as well as health-related quality-of-life. This study was designed to investigate the recurrence rate of atrial tachyarrhythmia (ATa), AF-related symptoms and HRQoL after PVI in patients with persistent AF who were treated with the second generation cryoballoon. METHODS: Total 148 patients participated in the study who were treated by PVI between 2013 and 2017 for persistent AF. All patients visited the out-patient clinic 2-5 years after PVI. During this visit all patients filled-out an AF Effect on Quality-of-life (AFEQT) questionnaire and a seven-day Holter was applied. All rhythm recordings acquired post ablation were collected and analysed, and the modified European Heart Rhythm Association score (mEHRA) scores were calculated before and after the ablation. RESULTS: The average age of patients was 63±9 year old and 44 (27.9%) were female. Mean CHA2DS2 VASc score was 1.9±1.4, and moderate and severe left atrial (LA) dilation was present in 53 (36.1%) and 15 (10.2%) patients, respectively. After a follow-up of 3.7±1.0 years, 81 (54.7%) patients had an ATa recurrence and 35 (23.6%) patients underwent a repeat LA ablation. However, the mEHRA score significantly improved in 80.4% of the patients (p <0.001), with the median overall AFEQT score of 88.9 [70.4-97.2]. CONCLUSIONS: There is a considerable ATa recurrence rate after PVI of persistent AF at intermediate-term follow-up. However, our data indicate that PVI significantly improved AF-related symptoms and resulted in a high HRQoL for 2-5 years in patients with persistent AF.
No takes yet. Share an insight, caveat, or question.
Mol et al. (2022) conducted a cross-sectional in Persistent atrial fibrillation (n=148). Second-generation cryoballoon pulmonary vein isolation was evaluated on Freedom of any atrial tachyarrhythmia (ATa). Second-generation cryoballoon ablation in patients with persistent atrial fibrillation resulted in a 54.7% recurrence of atrial tachyarrhythmia at 3.7 years, but significantly improved symptoms in 80.4% of patients.
Synapse has enriched 10 related papers. Consider them for comparative context: